GlassScriptPhysician profile
Luanda Y Perez
NPI 1285931113
$8,256.24
in general payments reported to CMS, 2019-2025
37 companies · $1,789 in 2025
The $1,789 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,659 · 2022: $1,906 · 2023: $1,663 · 2024: $1,240 · 2025: $1,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,299 · Education: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,299.22 |
| Education | $392.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,018.30 | 2021-2025 | Erleada, Carvykti, Rybrevant |
| Astellas Pharma US INC | $839.24 | 2021-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $815.24 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $703.89 | 2021-2025 | |
| Tolmar Pharmaceuticals, INC. | $508.09 | 2021-2022 | |
| Abbvie INC. | $480.29 | 2021-2025 | |
| Rochester Medical Corporation | $369.08 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $360.46 | 2022-2025 | |
| Boston Scientific Corporation | $309.54 | 2021-2023 | Spaceoar Vue System - 10ml |
| Verity Pharmaceuticals INC. | $245.21 | 2022-2025 | Tlando, Trelstar |
| Urovant Sciences INC | $223.50 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $182.16 | 2021 | |
| Tolmar, INC. | $145.56 | 2023-2024 | |
| Telix Pharmaceuticals | $115.40 | 2023-2025 | Illuccix |
| Merck Sharp & Dohme LLC | $98.53 | 2021-2023 | Lynparza, Keytruda |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $72.84 | 2023 | Interstim |
| Myovant Sciences INC. | $72.42 | 2022 | |
| Myriad Genetic Laboratories, INC. | $60.31 | 2021-2025 | Prolaris |
| Astrazeneca Pharmaceuticals LP | $55.47 | 2024 | Lynparza |
| Acerus Pharmaceuticals Corporation | $53.24 | 2022 | |
| Clarus Therapeutics INC. | $51.92 | 2021 | |
| Antares Pharma, INC. | $49.88 | 2021-2024 | Xyosted |
| Axonics, INC. | $43.29 | 2022-2023 | Axonics |
| Dendreon Pharmaceuticals LLC | $41.66 | 2022 | |
| Coloplast Corp | $39.61 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $37.58 | 2025 | |
| Janssen Scientific Affairs, LLC | $34.55 | 2022 | |
| Blue Earth Diagnostics | $33.65 | 2021 | |
| 180 Medical, INC. | $27.41 | 2021 | |
| Progenics Pharmaceuticals, INC. | $26.19 | 2025 | |
| Procept Biorobotics Corporation | $24.39 | 2025 | |
| Vertical Pharmaceuticals, LLC | $23.23 | 2024 | Dsuvia |
| Endo USA, INC. | $22.65 | 2024 | Xiaflex |
| Davol INC. | $18.79 | 2023 | Arista Ah Flexitip |
| Mission Pharmacal Company | $18.71 | 2022 | |
| Immunitybio, INC. | $18.45 | 2025 | |
| Accord Healthcare, INC. | $15.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luanda Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.